Please wait while the formulary information is being retrieved.
ACIPHEX (rabeprazole sodium)
- gastroesophageal reflux disease
- ulcer of the duodenum
- excessive production of stomach acid
- heartburn
- increased stomach acid from systemic mastocytosis
- inflammation of the stomach lining caused by H. pylori
- multiple endocrine neoplasia
- ulcer of duodenum caused by bacteria Helicobacter pylori
- Zollinger-Ellison syndrome
rabeprazole 20 mg tablet,delayed release
- 1 tablet (20 mg) by oral route once daily swallowing whole. Do not crush, chew and/or divide.
20 mg tablet,delayed release
- 1 tablet (20 mg) by oral route once daily swallowing whole. Do not crush, chew and/or divide.
Duodenal ulcer
- 1 tablet (20 mg) by oral route once daily after the morning meal, swallowing whole. Do not crush, chew and/or divide.
- 1 tablet (20 mg) by oral route once daily for 4 weeks after the morning meal, swallowing whole. Do not crush, chew and/or divide.
Gastric hypersecretion with systemic mastocytosis
- 3 tablets (60 mg) by oral route once daily swallowing whole. Do not crush, chew and/or divide.
- 3 tablets (60 mg) by oral route 2 times per day swallowing whole. Do not crush, chew and/or divide.
- 5 tablets (100 mg) by oral route once daily swallowing whole. Donot crush, chew and/or divide.
Gastroesophageal reflux disease
- 1 tablet (20 mg) by oral route once daily swallowing whole. Do not crush, chew and/or divide.
- 1 tablet (20 mg) by oral route once daily for 4 weeks swallowingwhole. Do not crush, chew and/or divide.
- 1 tablet (20 mg) by oral route once daily for 8 weeks swallowingwhole. Do not crush, chew and/or divide.
Heartburn
- 1 tablet (20 mg) by oral route once daily swallowing whole. Do not crush, chew and/or divide.
- 1 tablet (20 mg) by oral route once daily for 4 weeks swallowingwhole. Do not crush, chew and/or divide.
- 1 tablet (20 mg) by oral route once daily for 8 weeks swallowingwhole. Do not crush, chew and/or divide.
Helicobacter pylori gastritis
- 1 tablet (20 mg) by oral route every 12 hours in combination with amoxicillin and clarithromycin
- 1 tablet (20 mg) by oral route every 12 hours for 7 days in combination with amoxicillin and clarithromycin
Multiple endocrine neoplasia
- 3 tablets (60 mg) by oral route once daily swallowing whole. Do not crush, chew and/or divide.
- 3 tablets (60 mg) by oral route 2 times per day swallowing whole. Do not crush, chew and/or divide.
- 5 tablets (100 mg) by oral route once daily swallowing whole. Donot crush, chew and/or divide.
Pathological gastric acid hypersecretory condition
- 3 tablets (60 mg) by oral route once daily swallowing whole. Do not crush, chew and/or divide.
- 3 tablets (60 mg) by oral route 2 times per day swallowing whole. Do not crush, chew and/or divide.
- 5 tablets (100 mg) by oral route once daily swallowing whole. Donot crush, chew and/or divide.
Zollinger-ellison syndrome
- 3 tablets (60 mg) by oral route once daily swallowing whole. Do not crush, chew and/or divide.
- 3 tablets (60 mg) by oral route 2 times per day swallowing whole. Do not crush, chew and/or divide.
- 5 tablets (100 mg) by oral route once daily swallowing whole. Donot crush, chew and/or divide.
- atazanavir
- Complera
- Edurant
- emtricitab-rilpivirine-tenofov
- nelfinavir
- Reyataz
- rilpivirine
- Viracept
Contraindicated
- Bosulif
- bosutinib
- Cellcept
- Cellcept Intravenous
- dasatinib
- erlotinib
- itraconazole
- ketoconazole
- methotrexate sodium
- methotrexate sodium (PF)
- mycophenolate mofetil
- mycophenolate mofetil HCl
- nilotinib
- Noxafil
- Onmel
- posaconazole
- Sporanox
- Sporanox Pulsepak
- Sprycel
- Tarceva
- Tasigna
Severe
Moderate
- Adderall
- Adderall Xr
- Amphetamine Salt Combo
- Astagraf Xl
- Dexedrine Spansule
- dextroamphetamine
- dextroamphetamine-amphetamine
- Hecoria
- Methotrexate (anti-rheumatic)
- Procentra
- Prograf
- Rheumatrex
- tacrolimus
- Trexall
- Zenzedi
- None
Contraindicated
- Clostridioides difficile infection
- Disease of liver
- Interstitial nephritis
- Subacute cutaneous lupus erythematosus
- Systemic lupus erythematosus
Severe
Moderate
- CYp2c19 poor metabolizer
- Fracture
- Hypocalcemia
- Hypomagnesemia
- Osteoporosis
- Vitamin b12 deficiency
ACIPHEX (rabeprazole sodium)
- gastroesophageal reflux disease
- ulcer of the duodenum
- excessive production of stomach acid
- heartburn
- increased stomach acid from systemic mastocytosis
- inflammation of the stomach lining caused by H. pylori
- multiple endocrine neoplasia
- ulcer of duodenum caused by bacteria Helicobacter pylori
- Zollinger-Ellison syndrome
- Infection
- Abdominal pain with cramps
- Constipation
- Flatulence
- Headache disorder
- Pain
- Pharyngitis
More Frequent
Severe
Less Severe
- Abnormal hepatic function tests
- Arthralgia
- Diarrhea
- Dizziness
- Myalgia
- Nausea
- Peripheral edema
- Vomiting
- Xerostomia
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute generalized exanthematous pustulosis
- Agranulocytosis
- Anaphylaxis
- Angioedema
- Bullous dermatitis
- Clostridioides difficile infection
- Coma
- DRESS syndrome
- Fracture
- Hemolytic anemia
- Hepatitis
- Hyperammonemia
- Hypocalcemia
- Hypokalemia
- Hyponatremia
- Interstitial nephritis
- Interstitial pneumonitis
- Jaundice
- Leukopenia
- Pancytopenia
- Rhabdomyolysis
- Stevens-johnson syndrome
- Subacute cutaneous lupus erythematosus
- Systemic lupus erythematosus
- Thrombocytopenic disorder
- Toxic epidermal necrolysis
Less Severe
- Acute confusion
- Benign fundic gland polyposis of stomach
- Blurred vision
- Delirium
- Erythema multiforme
- Hypomagnesemia
- Vertigo
- Vitamin b12 deficiency
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Rabeprazole
Efficacy not demonstrated age <1 year. Fever and increased gastrin level observed in infant studies.
- 1 Day – 364 Days
- Efficacy not demonstrated age <1 year. Fever and increased gastrin level observed in infant studies.
Rabeprazole
- Severity Level:
2
- Additional Notes: Insuff human data; animal data suggest low risk
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Rabeprazole
Insuff data avail; low mw excretion possible
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insuff data avail; low mw excretion possible |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Rabeprazole
General-Prolonged use may dec absorption of Vitamin B-12. Avoid for >8 weeks duration unless for high risk patients (eg. oral corticosteroids or chronic NSAID use), erosive esophagitis, Barrett's esophagitis, pathologic hypersecretory condition, or demonstrated need for maint treatment. Musculoskeletal-Inc risk of fracture with high dose or use > 1 year. Gastrointestinal-Long term use may be assoc w/ C. difficile or GI malignancy. Pulmonary-Long term use may be assoc w/ pneumonia.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | N | N | Y | N |
BEERS: Y HEDIS: N STOPP: Y
No Known Risk
None
- None
| Duodenal ulcer | |
| K26 | Duodenal ulcer |
| K26.0 | Acute duodenal ulcer with hemorrhage |
| K26.1 | Acute duodenal ulcer with perforation |
| K26.2 | Acute duodenal ulcer with both hemorrhage and perforation |
| K26.3 | Acute duodenal ulcer without hemorrhage or perforation |
| K26.4 | Chronic or unspecified duodenal ulcer with hemorrhage |
| K26.5 | Chronic or unspecified duodenal ulcer with perforation |
| K26.6 | Chronic or unspecified duodenal ulcer with both hemorrhage and perforation |
| K26.7 | Chronic duodenal ulcer without hemorrhage or perforation |
| K26.9 | Duodenal ulcer, unspecified as acute or chronic, without hemorrhage or perforation |
| Duodenal ulcer due to h. pylori | |
| B96.81 | Helicobacter pylori [h. pylori] as the cause of diseases classified elsewhere |
| Gastric hypersecretion with systemic mastocytosis | |
| C96.21 | Aggressive systemic mastocytosis |
| D47.02 | Systemic mastocytosis |
| K31.89 | Other diseases of stomach and duodenum |
| Gastroesophageal reflux disease | |
| K21 | Gastro-esophageal reflux disease |
| K21.0 | Gastro-esophageal reflux disease with esophagitis |
| K21.00 | Gastro-esophageal reflux disease with esophagitis, without bleeding |
| K21.9 | Gastro-esophageal reflux disease without esophagitis |
| Heartburn | |
| R12 | Heartburn |
| Helicobacter pylori gastritis | |
| B96.81 | Helicobacter pylori [h. pylori] as the cause of diseases classified elsewhere |
| Multiple endocrine neoplasia | |
| E31.2 | Multiple endocrine neoplasia [MEn] syndromes |
| E31.20 | Multiple endocrine neoplasia [MEn] syndrome, unspecified |
| E31.21 | Multiple endocrine neoplasia [MEn] type I |
| E31.22 | Multiple endocrine neoplasia [MEn] type IIA |
| E31.23 | Multiple endocrine neoplasia [MEn] type IIB |
| Pathological gastric acid hypersecretory condition | |
| K31.89 | Other diseases of stomach and duodenum |
| Zollinger-ellison syndrome | |
| E16.4 | Increased secretion of gastrin |
| 0-9 | A-Z |
|---|---|
| B96.81 | Helicobacter pylori [h. pylori] as the cause of diseases classified elsewhere |
| B96.81 | Helicobacter pylori [h. pylori] as the cause of diseases classified elsewhere |
| C96.21 | Aggressive systemic mastocytosis |
| D47.02 | Systemic mastocytosis |
| E16.4 | Increased secretion of gastrin |
| E31.2 | Multiple endocrine neoplasia [MEn] syndromes |
| E31.20 | Multiple endocrine neoplasia [MEn] syndrome, unspecified |
| E31.21 | Multiple endocrine neoplasia [MEn] type I |
| E31.22 | Multiple endocrine neoplasia [MEn] type IIA |
| E31.23 | Multiple endocrine neoplasia [MEn] type IIB |
| K21 | Gastro-esophageal reflux disease |
| K21.0 | Gastro-esophageal reflux disease with esophagitis |
| K21.00 | Gastro-esophageal reflux disease with esophagitis, without bleeding |
| K21.9 | Gastro-esophageal reflux disease without esophagitis |
| K26 | Duodenal ulcer |
| K26.0 | Acute duodenal ulcer with hemorrhage |
| K26.1 | Acute duodenal ulcer with perforation |
| K26.2 | Acute duodenal ulcer with both hemorrhage and perforation |
| K26.3 | Acute duodenal ulcer without hemorrhage or perforation |
| K26.4 | Chronic or unspecified duodenal ulcer with hemorrhage |
| K26.5 | Chronic or unspecified duodenal ulcer with perforation |
| K26.6 | Chronic or unspecified duodenal ulcer with both hemorrhage and perforation |
| K26.7 | Chronic duodenal ulcer without hemorrhage or perforation |
| K26.9 | Duodenal ulcer, unspecified as acute or chronic, without hemorrhage or perforation |
| K31.89 | Other diseases of stomach and duodenum |
| K31.89 | Other diseases of stomach and duodenum |
| R12 | Heartburn |
Formulary Reference Tool